


PRODUCT: ENMD-2076**ALTERNATE NAMES:** 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine**CATALOG NUMBER:** B1938-5,25**AMOUNT:** 5 mg, 25 mg**STRUCTURE:****MOLECULAR FORMULA:** C₂₁H₂₅N₇**MOLECULAR WEIGHT:** 375.47**CAS NUMBER:** 934353-76-1**APPEARANCE:** Crystalline solid**SOLUBILITY:** DMSO (~ 18 mg/ml)**PURITY:** ≥98% by HPLC**STORAGE:** Store at -20 °C. Protect from air and light**DESCRIPTION:** ENMD-2076 is a selective inhibitor of Aurora A and Flt3 with IC₅₀ values of 14 and 1.86 nM, respectively. Displays 5-fold selectivity for Aurora A than over Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFR α .**REFERENCES:** Fletcher, G.C., *et al.* (2011). *Mol Cancer Ther.* **10**, 126-137.**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**

AT-9823 (Cat. No. 2432-5, 25)
Aurora Kinase B Inhibitor (Cat. No. 1583-5, 25)
AZD1480 (Cat. No. 2315-1, 5)
CCT-129202 (Cat. No. B1934-5,25)
CCT-137690 (Cat. No. B1935-5,25)
CP-690550 (Cat. No. 1622-5, 25)
CYC-116 (Cat. No. B1936-5,25)
Danusertib (Cat. No. B1937-5,25)
ENMD-2076 (Cat. No. B1938-5,25)
Lestaurtinib (Cat. No. 1805-500, 1000)
MLN8237 (Cat. No. 2718-5,25)
LLL12 (Cat. No. 1792-5, 25)
MS-1020 (Cat. No. 1911-1)
PF-03814735 (Cat. No. B1257-1,5)
Reversine (Cat. No. 1851-1, 5)
Ruxolitinib, free base (Cat. No. 2139-5, 25)
Tozasertib (Cat. No. 1595-25, 100)
EZSolution™ Tozasertib (Cat. No. 1803-TC-S 7010 (Cat. No. B1203-5,25)
TG101348 (Cat. No. 2314-1, 5)
Tyrphostin AG 490 (Cat. No. 1570-5)
WHI-P131 (Cat. No. 1853-5, 25)
WP1066 (Cat. No. 1809-5, 25)

USAGE: *FOR RESEARCH USE ONLY! Not to be used in humans*